264 related articles for article (PubMed ID: 16343627)
1. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.
Adamis AP; Altaweel M; Bressler NM; Cunningham ET; Davis MD; Goldbaum M; Gonzales C; Guyer DR; Barrett K; Patel M;
Ophthalmology; 2006 Jan; 113(1):23-8. PubMed ID: 16343627
[TBL] [Abstract][Full Text] [Related]
2. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
Cunningham ET; Adamis AP; Altaweel M; Aiello LP; Bressler NM; D'Amico DJ; Goldbaum M; Guyer DR; Katz B; Patel M; Schwartz SD;
Ophthalmology; 2005 Oct; 112(10):1747-57. PubMed ID: 16154196
[TBL] [Abstract][Full Text] [Related]
3. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.
Sultan MB; Zhou D; Loftus J; Dombi T; Ice KS;
Ophthalmology; 2011 Jun; 118(6):1107-18. PubMed ID: 21529957
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
5. Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham.
Loftus JV; Sultan MB; Pleil AM;
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7498-505. PubMed ID: 21896838
[TBL] [Abstract][Full Text] [Related]
6. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion.
Wroblewski JJ; Wells JA; Gonzales CR
Am J Ophthalmol; 2010 Jan; 149(1):147-54. PubMed ID: 19875087
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema.
Querques G; Bux AV; Martinelli D; Iaculli C; Noci ND
Acta Ophthalmol; 2009 Sep; 87(6):623-30. PubMed ID: 19678810
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
10. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
; Chakravarthy U; Adamis AP; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Patel M
Ophthalmology; 2006 Sep; 113(9):1508.e1-25. PubMed ID: 16828500
[TBL] [Abstract][Full Text] [Related]
11. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
Wroblewski JJ; Wells JA; Adamis AP; Buggage RR; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Altaweel MM;
Arch Ophthalmol; 2009 Apr; 127(4):374-80. PubMed ID: 19365011
[TBL] [Abstract][Full Text] [Related]
12. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
[TBL] [Abstract][Full Text] [Related]
14. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).
Jorge R; Costa RA; Calucci D; Cintra LP; Scott IU
Retina; 2006; 26(9):1006-13. PubMed ID: 17151487
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
Spaide RF; Fisher YL
Retina; 2006 Mar; 26(3):275-8. PubMed ID: 16508426
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy.
Ferraz DA; Vasquez LM; Preti RC; Motta A; Sophie R; Bittencourt MG; Sepah YJ; Monteiro ML; Nguyen QD; Takahashi WY
Retina; 2015 Feb; 35(2):280-7. PubMed ID: 25272318
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab.
Ebneter A; Wolf S; Zinkernagel MS
Br J Ophthalmol; 2016 Mar; 100(3):365-70. PubMed ID: 26187951
[TBL] [Abstract][Full Text] [Related]
19. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
Tatlipinar S; Dinç UA; Yenerel NM; Görgün E
Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975
[TBL] [Abstract][Full Text] [Related]
20. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
Domalpally A; Ip MS; Ehrlich JS
Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
